RELIEF THERAPEUTICS Holding Ltd.
RLF
ISIN CH1251125998 / Valor 125112599
RELIEF THERAPEUTICS Holding Ltd.
UMushroom community rating:
About company
RELIEF THERAPEUTICS Holding Ltd. is a Swiss biopharmaceutical company focused on identifying, developing, and commercializing novel, patent-protected products in specialty, rare, and ultra-rare disease areas worldwide. The company is currently in the commercial-stage and is dedicated to bringing innovative treatments to patients in need.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (06.11.2025):
In its 2024 Annual Report, RELIEF THERAPEUTICS Holding Ltd.’s update reflects a year of building a stronger foundation, marked by operational achievements, significant pipeline progress, and a reinforced financial position. The report highlights the company’s success in executing its commercial strategy alongside advances in key clinical candidates, positioning the company for upcoming regulatory and clinical milestones in early 2025.
Operational Achievements
The Annual Report underscores a series of operational milestones that have strengthened the company’s foundation, setting the stage for further progress in its specialty and rare disease treatment efforts throughout 2024.
Pipeline Advancements
Key candidates such as RLF-OD032 for phenylketonuria and RLF-TD011 for epidermolysis bullosa have made significant strides, reflecting the company’s commitment to expanding its portfolio with innovative treatment options.
Strengthened Financial Position
RELIEF THERAPEUTICS Holding Ltd.’s report emphasizes its improved financial standing, which supports continued investments in clinical development and commercial strategies, ultimately contributing to the company’s long-term growth and sustainability.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
46 M
Market cap (USD)
23,183
Daily traded volume (Shares)
4.59 / 4.26
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
